
Celldex Therapeutics (CLDX) Stock Forecast & Price Target
Celldex Therapeutics (CLDX) Analyst Ratings
Bulls say
Celldex Therapeutics has demonstrated a strong financial position, ending the year with $725.3 million in cash, which is expected to support ongoing operations through 2027. The company's lead candidate, barzolvolimab, has shown significant potential in clinical trials, particularly in improving quality of life for patients with chronic spontaneous urticaria and related conditions. With promising data indicating rapid improvement in urticaria control and a potential to enhance dysphagia outcomes, Celldex is well-positioned to make strides in the immunotherapy market across various indications.
Bears say
The financial outlook for Celldex Therapeutics appears negative due to substantial risks associated with clinical development and the potential for failure in demonstrating the necessary efficacy and safety profiles required for regulatory approval. Additionally, the company faces significant challenges in execution that could limit commercial success and market potential, alongside a dependency on securing adequate funding to continue its drug development programs. Furthermore, the competitive landscape may further constrain the adoption of their innovative therapies, increasing the overall uncertainty surrounding the firm's future financial performance.
This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Celldex Therapeutics (CLDX) Analyst Forecast & Price Prediction
Start investing in Celldex Therapeutics (CLDX)
Order type
Buy in
Order amount
Est. shares
0 shares